Urology Study Shows Reduced Side Effects from Radiation for Prostate Cancer with Calypso Medical Technologies's Tumor Tracking Technology

SEATTLE--(BUSINESS WIRE)--Calypso Medical Technologies, Inc., a developer of targeting technology used for accurate, precise real-time tracking of tumor targets, today announced the online publication of a clinical study in Urology (The GOLD JOURNAL). The prospective, multi-site study, entitled, “Assessing the Impact of Margin Reduction (AIM),” is the first outcomes-based study to evaluate the quality of life of high-dose intensity-modulated radiotherapy (IMRT) to the prostate with tightly contoured treatment technically described as “reduced treatment margins.” The study findings demonstrate that the use of the Calypso System during high dose external beam radiation for prostate cancer resulted in a significant reduction in rectal and urinary treatment-related side effects.

Back to news